

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils

E-J D Oudijk, E H J Nijhuis, M D Zwank, E A van de Graaf, H J Mager, P J Coffe, J-W J Lammers, L Koenderman

Thorax 2005;60:538-544. doi: 10.1136/thx.2004.034009

See end of article for authors' affiliations

Correspondence to:
L Koenderman, PhD,
Department of Pulmonary
Diseases (E03.406),
University Medical Centre,
Heidelberglaan 100, 3584
CX Utrecht, The
Netherlands;
l.koenderman@hli.azu.nl

Received
1 September 2004
Accepted
17 February 2005

Background: The inflammatory process in chronic obstructive pulmonary disease (COPD) is characterised by the presence of neutrophils in the lung that are able to synthesise de novo several inflammatory mediators. The local chronic persistent inflammatory response is accompanied by systemic effects such as cytokine induced priming of peripheral leucocytes and muscle wasting. The preactivation or priming of peripheral blood neutrophils was used to gain more insight into the mechanisms of this systemic inflammatory response.

Methods: Gene arrays were performed on peripheral blood neutrophils obtained from healthy donors after stimulation in vitro with tumour necrosis factor (TNF)- α , granulocyte-macrophage colony stimulating factor (GM-CSF), or both. The expression of many inflammatory genes was regulated in these cells following stimulation. The expression of inflammatory genes in peripheral blood neutrophils in healthy subjects and those with COPD was measured by real time RT-PCR after stimulation with TNF α , GM-CSF, interleukin (IL)-8, fMLP, TNF α + GM-CSF, and lipopolysaccharide (LPS).

Results: The genes regulated in the gene array with TNF α /GM-CSF stimulated neutrophils included cytokines (such as IL-1 β), chemokines (such as IL-8), and adhesion molecules (such as ICAM-1). Disease severity as measured by forced expiratory volume in 1 second (FEV₁) in COPD patients correlated with expression of several of these genes including IL-1 β ($r = -0.540$; $p = 0.008$), MIP-1 β ($r = -0.583$; $p = 0.003$), CD83 ($r = -0.514$; $p = 0.012$), IL-1 receptor 2 ($r = -0.546$; $p = 0.007$), and IL-1 receptor antagonist ($r = -0.612$; $p = 0.002$).

Conclusions: These data are consistent with the hypothesis that progression of COPD is associated with the activation of neutrophils in the systemic compartment. De novo expression of inflammatory mediators by peripheral blood neutrophils suggests a pro-inflammatory role for these cells in the pathogenesis of COPD.

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease of the airways which is characterised by the presence of chronic airflow obstruction and an abnormal inflammatory response in the pulmonary tissue.^{1,2} The aberrant inflammatory process is characterised by increased levels of cytokines and/or chemokines such as tumour necrosis factor (TNF)- α and interleukin (IL)-8.^{3,4} Furthermore, an increase in neutrophils, monocytes, and CD8+ cytotoxic lymphocytes is found in the pulmonary compartment.^{5,6} This increase in inflammatory cells is likely to be mediated by the increased levels of cytokines and/or chemokines in the tissue. In addition, the presence of these cytokines in the plasma/serum of patients with COPD strongly suggests that the local inflammatory response communicates via these mediators with the systemic circulation.⁷⁻¹⁰

Systemic effects are initiated by the persistent local inflammatory response in COPD patients. In contrast to the local inflammation, little is known concerning the systemic inflammatory response in COPD. The identification of soluble TNF receptors (which are thought to counteract the function of TNF α) in the plasma of patients with COPD corroborates the idea that the local inflammation in the airways communicates with the systemic compartment.⁴ Unfortunately, direct measurement of many inflammatory mediators such as TNF α is difficult in the peripheral blood because of their low concentration, short half life, binding to soluble receptors, and renal clearance.¹¹ Alternatively, a few studies have reported that neutrophils in the peripheral blood of COPD patients exhibit characteristics of a primed phenotype.^{12,13}

These findings suggest that the activation of neutrophils may start in the circulation. However, the underlying pathogenetic mechanisms remain to be determined.

New methods that allow monitoring of neutrophil activation and analysis of inflammatory mediators are important for the characterisation of the systemic inflammatory response in COPD. We and others have shown that in vitro priming of neutrophils with, for example, granulocyte-macrophage colony stimulating factor (GM-CSF) is associated with the expression of specific gene profiles.^{14,15} The investigation of gene expression profiles of peripheral blood neutrophils of COPD patients in comparison with in vitro cytokine induced gene profiles of neutrophils could therefore be a powerful tool for characterising chronic systemic inflammation in COPD.

In this study peripheral blood neutrophils of healthy donors stimulated with TNF α , GM-CSF, or both were examined by analysis of cytokine regulated gene profiles in vitro using gene arrays. Further investigation of differentially expressed genes such as several IL-1 family members, macrophage inflammatory protein (MIP)-1 β , and CD83 in patients with mild and severe COPD showed that the expression of these genes in peripheral blood neutrophils correlates with the severity of COPD.

METHODS

Reagents

fMLP and LPS (*E coli*) were purchased from Sigma (St Louis, MO, USA), recombinant human GM-CSF from Genzyme (Boston, MA, USA), recombinant human TNF α from

Table 1 Characteristics of study patients

	COPD (n = 23)	Controls (n = 11)
Age (years)	64.0 (2.3)	34.8 (2.6)
Sex (M/F)	14/9	4/7
FEV ₁ (% predicted)	51.7 (3.8)	100.9 (2.5)
VC (% predicted)	85.3 (4.2)	100.7 (1.9)
WBC ($\times 10^5$ /l)	9.0 (1.3)	6.1 (0.3)
CRP* (mg/l)	10 (7–16)	<5 (<5–7)
BMI (kg/m ²)	25.3 (0.7)	22.6 (0.6)
Pack years	40.0 (4.1)	–
Current smokers	11	–

FEV₁, forced expiratory volume in 1 second; VC, vital capacity; WBC, white blood cells; CRP, C reactive protein; BMI, body mass index. Data shown are mean (SD) values except for *median (range).

Boehringer Mannheim (Germany), IL-8 from Peprotech (Rocky Hill, NJ, USA), human serum albumin (HSA) was obtained from the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (Amsterdam, The Netherlands), RPMI 1640 medium with glutamax was purchased from Life Technologies (Breda, The Netherlands), and Ficoll-Paque was from Pharmacia (Uppsala, Sweden).

Preparation of samples

Blood was obtained from healthy volunteers and COPD patients. Granulocytes were isolated as described previously.¹⁶ Neutrophils used for in vitro stimulation experiments as well as for RNA isolation were incubated in RPMI 1640 glutamax supplemented with 0.5% HSA for 15 minutes before stimulation or further preparation. RNA isolation and cDNA synthesis were performed as previously described.¹⁶ All preparations contained >97% neutrophils, and contaminating cells were mainly eosinophils.

Subjects

Twenty three patients with clinically stable moderate to very severe COPD were included in the study. COPD was defined according to the criteria of the GOLD guidelines.^{1,2} Inclusion criteria were forced expiratory volume in 1 second (FEV₁) <80%, reversibility of less than 10% or less than 200 ml after inhalation of a β_2 agonist, and a FEV₁/FVC ratio of less than 70% of the predicted value. Subjects with a history of other concomitant confounding diseases such as diabetes mellitus, lung carcinoma, thyroid and cardiovascular disease and those with bronchiectasis were excluded from the study. Patients with an exacerbation due to a respiratory tract infection or other respiratory complaints during the 4 weeks before the study or those with a history of asthma or atopy were also excluded. Eleven patients were current smokers while the rest had stopped smoking at least 1 year before the study. Details of the patients are shown in table 1.

Fourteen of the 23 patients met the criteria for moderate COPD (class II according to the GOLD guidelines) while the other nine had severe to very severe COPD (class III and IV). All patients were treated with inhaled long acting β_2 agonists (salmeterol 50 μ g twice daily), inhaled corticosteroids (250 μ g twice daily), and additional bronchodilating agents if needed. Regular use of oral glucocorticosteroids was an exclusion criterion. Eleven healthy never smokers were enrolled as controls, all of whom had normal lung function and no medical history of pulmonary diseases.

The study was approved by the medical ethics committee of the University Medical Center, Utrecht and informed consent was obtained from all subjects.

Gene array analysis

Isolated human neutrophils were incubated in RPMI 1640 supplemented with 0.5% HSA for 15 minutes and stimulated for 3 hours at 37°C in the presence or absence of cytokines, followed by RNA isolation as described previously. RNA was treated with DNase to avoid contamination with genomic DNA and subsequently analysed by agarose gel electrophoresis to verify the integrity of the RNA preparations. PolyA+ RNA was extracted with magnetic beads coated with poly dT using the Atlas Pure Total RNA Labeling System (Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol. 40 μ g of total RNA from neutrophils was used for each gene array. The gene array screen was performed with the Atlas Human Hematology/Immunology Array #7737-1 (Clontech) using reagents supplied and the manufacturer's protocol. Briefly, cDNA probes were generated using specific primers for the genes on the array. Reverse transcription of the isolated polyA+ RNA was performed with radioactive γ^{32} P-dATP. The two arrays were incubated overnight with the probe at 68°C. The following day the arrays were washed and membranes analysed by autoradiography. The spots on the arrays were quantitated using a Phosphor Imager and ImageQuant software (Amersham Biosciences, Uppsala, Sweden). Values were corrected for background and house-keeping genes.

Real time PCR

Gene expression was analysed by real time RT-PCR. For CD83 the Taqman probe procedure was used; all other genes were analysed with SYBR green I. For β -actin we used primers as described previously.¹⁷ All other primers were designed using Primer 3 software from the Whitehead Institute/MIT Center for Genome Research (http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) and are shown in table 2. The results were normalised for the housekeeping gene β -actin and GAPDH. A reference sample of cDNA on every 96-well plate allowed correction of differences between plates.

Statistics

Statistical analysis was performed with SPSS 10.0. Multiple comparisons were analysed by analysis of variance (one

Table 2 Sequences of primers used for real time PCR (SYBR green)

Target sequence	Forward primer	Reverse primer
GAPDH	AGAAGGCTGGGGCTCATT	GAGGCATTGCTGATGATCTTG
MIP-1 β	CCATGAAGCTCTGCGTGACT	AGCCCATGGTGCTGAGAG
IL-1 β	GCTTATTACAGTGGCAATGAGGAT	GGTGGTCGGAGATTCGTAGC
IL-1RA	GAAGATGTGCTGCTCTGTGTC	CGCTGTGCTGCTTCTGTTC
IL-1R2	CAGGAGGACTCTGGCACTAC	TGAGATGAACGGCAGGAAAG
IL-8	AGCTCTGTGTAAGGTGCAGTT	GGGTGAAAGGTTTGGAGTATG
IL-8R1	TCAAGTGCCCTAGCTGTTAAGT	TCTTCAGTTTCAGCAATGGTTTG

Table 3 Genes regulated by several stimuli in neutrophils of healthy donors (n = 2)

Description	Genbank number	TNF α (fold change)	GM-CSF (fold change)	TNF α + GM-CSF (fold change)
Chemokine/cytokine receptors				
IL-8R α	M68932	-8.6		-6.4
IL-1R β	X59770	11.5	13.6	4.4
Blood disorder proteins				
Antileukoproteinase (ALP) 1	X04470	5.1		
Retinoic acid receptor α (RAR- α)	M73779		15.0	
B cell translocation gene 1 (BTG1)	X61123		-10.3	-9.2
NOTCH 1	M73980	-4.5	-6.4	-5.8
Chemokines/cytokines				
IL-1 β	K02770	13.0	27.3	
IL-1RA	M63099	106.7	98.5	227.6
IL-8	Y00787	7.1	9.3	22.2
MIP-1 β	J04130	6.0		4.1
Lymphotoxin- β	L11015		3.2	
Surface antigens				
ICAM-1	J03132	15.4	5.0	18.1
CD14 antigen	M86511	2.8	9.5	4.5
CD44 antigen	M59040	8.7	21.6	16.6
CD58 antigen	Y00636	3.4	6.7	3.5
CD83 antigen	Z11697	12.5		10.3
CD69 antigen	L07555		17.4	8.2
Transcription factors				
MNDA	M81750		-4.4	-11.8
STAT5A/B	U47686		-5.7	
fli1 proto-oncogene	M93255	-3.1	-6.9	-16.3
Protein kinases/oncogenes				
vav2	S76992		12.0	10.7
SLP-76	U20158	3.3	15.2	15.1
ras-like small GTPase TTF	Z35227			8.2
Apoptosis				
BCL2-related protein A1 (BCL2-A1)	U29680	13.9	4.7	19.2

TNF α , tumour necrosis factor α ; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, interleukin; IL-8R α , IL-8 receptor α ; IL-1R β , IL-1 receptor β ; IL-1RA, IL-1 receptor antagonist; MIP, macrophage inflammatory protein. Neutrophils were incubated with TNF α (100 U/ml) and/or GM-CSF (0.1 nM) for 3 hours in vitro. RNA was isolated and used for generating radioactively labelled cDNA which was hybridised with Atlas array filters. Membranes were analysed using PhosphorImager and Image Quant software. Changes in gene expression are relative to control.

way ANOVA, Fisher test). In addition, the results were analysed using the Mann-Whitney U test. For the analysis of the data depicted in fig 1 a paired *t* test was used.

Correlation coefficients were calculated using Spearman's correlation coefficient. Statistical significance was defined as *p*<0.05.




Figure 1 Gene expression in peripheral blood neutrophils stimulated by several mediators in vitro. Peripheral blood neutrophils were incubated with several physiological stimuli for 3 hours in vitro at 37°C (TNF α , 100 U/ml; GM-CSF, 0.1 nM; IL-8, 10 nM; fMLP, 1 μ M; LPS, 10 ng/ml). Expression of indicated genes was measured by real time RT-PCR. The results are expressed as mean (SD) log2 fold change (n = 3). Differences between values were compared by the paired *t* test. **p*<0.05.

RESULTS

Modulation of inflammatory genes in neutrophils by TNF α and/or GM-CSF

To gain further insight into the mechanisms of neutrophil activation, we evaluated differential gene expression in healthy donor blood neutrophils activated with GM-CSF and TNF α in vitro. Table 3 shows the change after stimulation of neutrophils with the cytokines TNF α or GM-CSF separately or in combination compared with non-stimulated neutrophils. Most of the genes on the array encoded for cytokines/chemokines and cell surface receptors. Among the cytokines and chemokines, genes encoding for IL-8, IL-1 β , and IL-1 receptor antagonist (IL-1RA) were clearly upregulated by both TNF α and GM-CSF. On the other hand, more specific signals induced by the cytokines were shown by the regulation of MIP-1 β which was only induced by TNF α and by lymphotoxin- β which was only induced by GM-CSF. In addition, this analysis revealed that TNF α and GM-CSF both induced pro-inflammatory genes such as IL-1 β and IL-8, as well as anti-inflammatory genes such as IL-1RA and IL-1 receptor 2 (IL-1R2). Of the regulated cell surface antigens, most were upregulated by both TNF α and GM-CSF except for CD83 and CD69 which were only upregulated by TNF α or GM-CSF, respectively. The anti-apoptotic Bcl-2 family member A1 is involved in regulating cell survival and expression was already high directly after isolation, decreasing after 3 hours at 37°C in the absence of cytokines. Both TNF α and GM-CSF maintained the high expression of Bcl-A1.

The combination of TNF α and GM-CSF resulted in regulation of almost all genes which are regulated by TNF α and GM-CSF individually, but some genes were regulated only by the individual cytokines. MIP-1 β , CD83, IL-8R1, and antileukoproteinase (ALP) were only regulated by TNF α , whereas GM-CSF alone regulated retinoic acid receptor (RAR)- α , B cell translocation gene 1 (BTG1), lymphotoxin- β , CD69, MNDA, STAT5A/B, and vav2 (table 3).

The expression of MIP-1 β , IL-1RA, IL-1 β , IL-8, IL-8R1, and CD83 regulated on the gene array (see table 2) was confirmed by real time RT-PCR. Peripheral blood neutrophils of three healthy donors were stimulated with TNF α , GM-CSF, IL-8, fMLP, and LPS and gene expression was measured with real time RT-PCR (fig 1). Analysis revealed that IL-8 and fMLP did not induce any of the genes investigated except CD83. Upregulation of the mRNA for IL-1RA and IL-1 β was observed after stimulation of the cells with TNF α , GM-CSF, LPS, or co-stimulation with TNF α and GM-CSF. IL-1R2 was downregulated by all stimuli. Similar to the data obtained with the gene arrays, CD83 and MIP-1 β were upregulated by TNF α and not by GM-CSF.

Expression of TNF α and GM-CSF regulated genes in COPD patients

Real time RT-PCR analysis of gene expression in COPD patients and healthy controls is shown in fig 2. In neutrophils of patients with moderate COPD (GOLD class II) only the IL-8R1 gene was significantly decreased compared with healthy




Figure 2 Gene expression analysis in peripheral blood neutrophils of COPD patients. Peripheral blood neutrophils were isolated from healthy volunteers (filled squares), moderate (class II) COPD patients (open diamonds), and those with severe to very severe (class III and IV) stable COPD (filled triangles). Expression of indicated genes was measured using real time RT-PCR and expressed as log2 fold change compared with healthy controls. Differences between the study groups were compared using the one way ANOVA, Fisher test.




Figure 3 Correlation of gene expression in peripheral blood neutrophils of COPD patients with FEV₁ (% predicted). Expression of indicated genes was measured using real time RT-PCR and expressed as log₂ fold change compared with healthy controls. Correlations between FEV₁ and expression of indicated genes in neutrophils from patients with stable COPD were evaluated using Pearson's rank correlation analysis.

volunteers. In patients with more severe COPD a significant increase was seen in CD83, MIP-1β, and IL-1β compared with healthy volunteers. Furthermore, CD83, IL-1β, MIP-1β, and IL-1RA were significantly increased in patients with severe and very severe COPD compared with those with moderate COPD.

TNFα regulated genes correlated with severity of disease in patients with stable COPD. CD83 ($r = -0.51$), MIP-1β ($r = -0.58$), IL-1RA ($r = -0.61$), IL-1β ($r = -0.54$) and IL-1R2 ($r = -0.546$) correlated with the severity of COPD as measured by FEV₁ (fig 3). In contrast, there was no correlation between FEV₁ and the expression of IL-8 and IL-8R1 (results not shown). Current smoking status did not influence the gene expression in fig 3 and BMI did not correlate with severity of disease in patients with stable COPD (results not shown).

DISCUSSION

The chronic persistent inflammatory reaction in COPD patients is dominated by neutrophils which are effector cells that can also mediate the systemic effects of chronic inflammation.^{10–18} Investigation of gene expression in peripheral blood neutrophils of COPD patients could therefore provide a unique insight into the molecular mechanisms modulating chronic systemic inflammation. In this study the activation of peripheral blood neutrophils was examined by gene array analysis of cytokine stimulated neutrophils. mRNA expression of MIP-1β, IL-1RA, IL-1β, IL-8, IL-8R1, and CD83 in cytokine stimulated neutrophils and in neutrophils obtained from patients with COPD was measured with real time RT-PCR.

Gene expression analysis of peripheral blood neutrophils from patients with severe stable COPD indicated that

peripheral blood neutrophils exhibited an activated phenotype. Clear regulation of pro-inflammatory mediators was evident in patients with severe to very severe COPD (class III and IV, fig 2); several of these genes including IL-1β, IL-1R and MIP-1β have previously been reported to be regulated by pro-inflammatory mediators such as TNFα, GM-CSF, or LPS.^{19–21} Upregulation of CD83, which is described as a specific marker for dendritic cells, has recently been reported to be expressed on neutrophils in vitro by TNFα and in vivo by acute infection.^{22–23} These data are consistent with the hypothesis that circulating neutrophils in patients with severe COPD have encountered pro-inflammatory mediators.

The genes regulated in the neutrophils of normal subjects stimulated in vitro with TNFα and LPS were very similar to the genes regulated in the patients with COPD. However, the gene expression profile of neutrophils from COPD patients is not identical to the profile of individual mediators such as TNFα or LPS. It is unlikely that dominant single mediators drive systemic inflammation in COPD but, rather, a combination of inflammatory mediators. Indeed, a combination of inflammatory mediators can lead to enhancement or inhibition of the transcription of genes (fig 1). A clear example is the finding that interferon (IFN)-γ enhances the production of cytokines/chemokines of neutrophils stimulated by LPS while IL-10 inhibits their production.²⁰ In addition, the kinetics of gene expression could have an influence. Genes that are expressed relatively late upon activation might not be found in peripheral blood but only in cells that have migrated to the tissues.

Investigation of expression of several of these genes (including IL-1β, IL-1RA, IL-8, CD83 and MIP-1β) by real time RT-PCR in patients with different stages of COPD

revealed that these genes were significantly increased in patients with more severe disease (class III and IV) and there was a significant negative correlation between the extent of gene expression in peripheral blood neutrophils and lung function. This was not a generalised finding since this correlation did not exist for several other genes (results not shown). These data show a correlation between lung function impairment and the systemic inflammatory reaction as measured in the peripheral blood. Systemic inflammation can thus be measured as an additional marker for the health status and may also help to determine the prognosis of a patient with COPD. The genes which correlated with lung function did not correlate with other parameters such as body mass index (BMI) or cotinine levels in the current smokers (results not shown). Low BMI is often a major health problem in smokers with COPD but, in our study, the BMI levels were not significantly different from healthy controls.

It has been shown that, besides the traditional functions such as phagocytosis, degranulation and production of superoxide, neutrophils can express a variety of inflammatory mediators (reviewed by Cassatella²⁰). These findings suggest that circulating neutrophils not only participate in airway damage in COPD patients but also participate in the regulation of systemic inflammation.

TNF α , GM-CSF, and LPS can induce the expression of pro-inflammatory mediators in neutrophils and thereby enhance the inflammatory response. Natural inhibitory proteins such as IL-1RA and IL-1R2 inhibit IL-1 β induced pro-inflammatory responses. IL-1RA exerts its inhibitory action by binding to IL-1 receptors without triggering any intracellular signalling responses, whereas IL-1R2 is a decoy receptor and binds IL-1 β thereby competing for IL-1R expressed on inflammatory and/or bystander cells.^{24–25} Upregulation of IL-1RA and IL-1R2 in neutrophils *in vivo* is likely to be involved in dampening of the inflammatory response initiated by IL-1 β . Similarly, TNF α or GM-CSF downregulated the expression of IL-8R1 which is likely to result in reduced responsiveness to this pro-inflammatory chemokine. Other studies have shown that systemic inflammation can cause functional downregulation of serpentine receptors *in vitro* and *in vivo*.^{26–28} Thus, activated neutrophils not only induce a pro-inflammatory response but also an anti-inflammatory response, generating a negative feedback loop. The outcome of these two processes may be determined by differences in the levels and kinetics of the peripheral pro- and anti-inflammatory cytokines. Neutrophils are therefore not only effector cells but might also have a role in the regulation of the duration of an inflammatory reaction.

An interesting observation is the disturbed balance of mRNA expression between the pro-inflammatory mediator IL-1 β and the anti-inflammatory mediators IL-1RA and IL-1R2 in patients with severe stable COPD compared with *in vitro* where peripheral blood neutrophils are activated with inflammatory mediators. Real time RT-PCR analysis showed that the expression of IL-1RA is much higher than that of IL-1 β in neutrophils stimulated with TNF α (fig 1) compared with neutrophils from patients with severe stable COPD (fig 2). The regulation of natural inhibitory genes is apparently disturbed in peripheral blood neutrophils from patients with severe COPD. In addition, expression of IL-1R2 is not upregulated in these patients while, *in vitro*, GM-CSF and LPS induced expression of IL-1R2. The balance of expressed genes has therefore been shifted towards a pro-inflammatory state.

In contrast to rheumatoid arthritis, little is known about the function of the IL-1 family of proteins in COPD. In the rheumatoid synovium an imbalance exists in the pro- and anti-inflammatory mediators since the relative levels of production of IL-1RA are not adequate to block the

pro-inflammatory effects of IL-1 effectively.²⁹ Injection of IL-1RA into the synovium significantly reduced the signs and symptoms of rheumatoid arthritis after 24 weeks.³⁰ The imbalance between anti- and pro-inflammatory genes (including the IL-1 family) of circulating neutrophils might therefore also contribute to the development of a chronic inflammatory response in COPD.

Because of the relatively small sample size in this study, we could not evaluate putative correlations between measured variables and confounding factors such as age, circulating neutrophil number, or co-related smoking induced morbidity such as occult coronary artery disease. In a previous study performed by Malcolm *et al*,³¹ donor variability was observed by gene analysis in LPS stimulated neutrophils. We validated the genes regulated on the microarrays with real time RT-PCR in cytokine stimulated peripheral blood neutrophils of three healthy donors.

In the patients with COPD a single time point was studied. It would be interesting to study gene regulation during and after exacerbation of the disease, but this was beyond the scope of the present study. In addition, it would be interesting in future studies to compare cytokine induced gene profiles of other systemic inflammatory diseases such as rheumatoid arthritis with COPD.

In conclusion, this study indicates that activated neutrophils can be found in the peripheral blood of patients with stable COPD and this activation correlates with the severity of the disease. Inflammatory mediators such as TNF α are probably involved in the activation of neutrophils in these patients. Interestingly, there is an imbalance in the expression of pro- and anti-inflammatory mediators (including the IL-1 family) in the neutrophils of patients with more severe COPD. This imbalance towards a pro-inflammatory response may contribute to the systemic inflammation observed in these patients. Greater understanding of these mechanisms by fine tuning analysis of the gene profiles may increase our understanding of the systemic inflammation in COPD and may result in better markers for disease staging and prognosis.

Authors' affiliations

E J D Oudijk, E H J Nijhuis, M D Zwank, E A van de Graaf, P J Coffer, J-W J Lammers, L Koenderman, Department of Pulmonary Diseases, Heart Lung Center Utrecht, University Medical Center, Utrecht, The Netherlands

H J Mager, Department of Pulmonary Diseases, Heart Lung Center Utrecht, Mesos, The Netherlands

This work was supported by the Dutch Asthma Foundation (Grant 97.68) and ZonMW 9-40-37-035.

The first two authors contributed equally to the study.

REFERENCES

- 1 Pauwels RA, Buist AS, Calverley PM, *et al*. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001;**163**:1256–76.
- 2 Fabbri L, Pauwels RA, Hurd S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary updated 2003. *J COPD* 2004;**1**:105–41.
- 3 Cosio MG, Guerassimov A. Chronic obstructive pulmonary disease. Inflammation of small airways and lung parenchyma. *Am J Respir Crit Care Med* 1999;**160**:S21–5.
- 4 Verma JH, Kucukaycan M, Jacobs JA, *et al*. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. *Am J Respir Crit Care Med* 2002;**166**:1218–24.
- 5 Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F Filley Lecture. *Chest* 2000;**117**:251–60S.
- 6 O'Shaughnessy TC, Ansari TW, Barnes NC, *et al*. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV₁. *Am J Respir Crit Care Med* 1997;**155**:852–7.

- 7 Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. *Am J Respir Crit Care Med* 1997;**155**:449–53.
- 8 Pesci A, Balbi B, Majori M, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. *Eur Respir J* 1998;**12**:380–6.
- 9 Aaron SD, Angel JB, Lunau M, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;**163**:349–55.
- 10 Oudijk EJ, Lammers JW, Koenderman L. Systemic inflammation in chronic obstructive pulmonary disease. *Eur Respir J Suppl* 2003;**46**:5–13s.
- 11 Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor- α system in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;**161**:1179–84.
- 12 Noguera A, Batle S, Miralles C, et al. Enhanced neutrophil response in chronic obstructive pulmonary disease. *Thorax* 2001;**56**:432–7.
- 13 Koenderman L, Kanters D, Maesen B, et al. Monitoring of neutrophil priming in whole blood by antibodies isolated from a synthetic phage antibody library. *J Leukoc Biol* 2000;**68**:58–64.
- 14 Pals CM, Verploegen SA, Raaijmakers JA, et al. Identification of cytokine-regulated genes in human leukocytes in vivo. *J Allergy Clin Immunol* 2000;**105**:760–8.
- 15 Yousefi S, Cooper PR, Mueck B, et al. cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. *Biochem Biophys Res Commun* 2000;**277**:401–9.
- 16 Verploegen S, van Leeuwen CM, van Deutekom HW, et al. Role of Ca²⁺/calmodulin regulated signaling pathways in chemoattractant induced neutrophil effector functions. Comparison with the role of phosphatidylinositol-3 kinase. *Eur J Biochem* 2002;**269**:4625–34.
- 17 Kreuzer KA, Lass U, Landt O, et al. Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. *Clin Chem* 1999;**45**:297–300.
- 18 Stockley RA. Neutrophils and the pathogenesis of COPD. *Chest* 2002;**121**:151–55.
- 19 Fujishima S, Hoffman AR, Vu T, et al. Regulation of neutrophil interleukin 8 gene expression and protein secretion by LPS, TNF- α , and IL-1 β . *J Cell Physiol* 1993;**154**:478–85.
- 20 Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. *Adv Immunol* 1999;**73**:369–509.
- 21 Malyak M, Smith MF Jr, Abel AA, et al. Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1 β . *J Clin Immunol* 1994;**14**:20–30.
- 22 Yamashiro S, Wang JM, Yang D, et al. Expression of CCR6 and CD83 by cytokine-activated human neutrophils. *Blood* 2000;**96**:3958–63.
- 23 Iking-Konert C, Wagner C, Deneffle B, et al. Up-regulation of the dendritic cell marker CD83 on polymorphonuclear neutrophils (PMN): divergent expression in acute bacterial infections and chronic inflammatory disease. *Clin Exp Immunol* 2002;**130**:501–8.
- 24 Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. *Science* 1993;**261**:472–5.
- 25 Carter DB, Deibel MR Jr, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. *Nature* 1990;**344**:633–8.
- 26 Jawa RS, Quaid GA, Williams MA, et al. Tumor necrosis factor α regulates CXC chemokine receptor expression and function. *Shock* 1999;**11**:385–90.
- 27 Khandaker MH, Xu L, Rahimpour R, et al. CXCR1 and CXCR2 are rapidly down-modulated by bacterial endotoxin through a unique agonist-independent, tyrosine kinase-dependent mechanism. *J Immunol* 1998;**161**:1930–8.
- 28 Soejima K, Fujishima S, Nakamura H, et al. Downmodulation of IL-8 receptors, type A and type B, on human lung neutrophils in vivo. *Am J Physiol* 1997;**273**:L618–25.
- 29 Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. *Semin Arthritis Rheum* 2001;**30**:1–6.
- 30 Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. *Ann Rheum Dis* 2000;**59**(Suppl 1):i103–8.
- 31 Malcolm KC, Arndt PG, Manos EJ, et al. Microarray analysis of lipopolysaccharide-treated human neutrophils. *Am J Physiol Lung Cell Mol Physiol* 2003;**284**:L663–70.

Call for papers

11th European Forum on Quality Improvement in Health Care

26–28 April 2006, Prague, Czech Republic

Deadline 30 September 2005.

For further information and to submit online go to: www.quality.bmjpg.com